MG
FBRX icon

Michael Gelband’s Forte Biosciences FBRX Stock Holding History

Michael Gelband’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
10,223
-3,524
-26% -$83.6K ﹤0.01% 1414
2026
Q1 		$356K Buy
13,747
+2,663
+24% +$76.7K ﹤0.01% 1275
2025
Q4 		$302K Buy
+11,084
New +$194K ﹤0.01% 1311
2021
Q2 		– Sell
-1,801
Closed -$1.54M – 2490
2021
Q1 		$1.54M Buy
1,801
+608
+51% +$498K 0.02% 686
2020
Q4 		$1.09M Buy
+1,193
New +$1.12M 0.01% 806

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Michael Gelband's FBRX Position: Q2 2026 in Review

Michael Gelband reduced its Forte Biosciences (FBRX) stake by 26% in Q2 2026, selling an estimated $83.6K and leaving 10,223 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

Michael Gelband first reported a position in FBRX in Q4 2020 and has held it in 5 quarters since. The position peaked at $1.54M in Q1 2021. 85 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Michael Gelband held 10,223 shares of Forte Biosciences worth $217K as of Q2 2026.
  • Michael Gelband sold 3,524 Forte Biosciences shares in Q2 2026, an estimated $83.6K.
  • Forte Biosciences made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1414 holding.
  • Michael Gelband first reported a position in Forte Biosciences in Q4 2020 and has held it in 5 quarters since.
  • Michael Gelband's Forte Biosciences position peaked at $1.54M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.